Kaplan-Meier estimates of survival outcomes in older patients treated with low-intensity therapy. (A) RFS. (B) OS. (C) Impact of venetoclax added to low-intensity therapy on RFS. (D) Impact of venetoclax added to low-intensity therapy on OS. (E) RFS in secondary/therapy related AML. (F) OS in secondary/therapy related AM. (G) RFS in de novo AML. (H) OS in de novo AML. mOS, median OS; mRFS, median RFS; NAR, number at risk; Ven, venetoclax.